0 antall prosjekter

FRIMED2-FRIPRO forskerprosjekt, medisin og helse

Blocking regulatory T cells to restore immune function

Prosjektet tar sikte på å undersøke hvordan regulatoriske T celler hemmer T hjelperceller og T dreperceller, hvordan de demper immunsystemet og bidrar til å unngå autoimmunitet samt hvordan de kan utnyttes av kreftsvulster til å omgå anti-tumor immunitet. Vi utvikler metoder for å skru av og på r...

Tildelt: kr 11,9 mill.

Prosjektperiode: 2021-2024

Sted: Oslo

FORNY20-FORNY2020

MP: Aminoacridines with dual SARS-CoV2 antiviral and immunostimulating activity

En gruppe kjemiske stoffer som regulerer og som potensielt kan bedre anti-virale immunresponser ved Covid-19 infeksjon ble undersøkt. I tillegg hadde stoffene en direkte hemmende effekt på SARS-Cov2 viruset i testsystemet i laboratoriet og basert på karakterisering av disse effektene ble tre lege...

Tildelt: kr 0,50 mill.

Prosjektperiode: 2020-2021

Sted: Oslo

FORNY20-FORNY2020

MP: Novel treatment for patients with glioblastoma

Hjernekreft, glioblastom, er en av de mest dødelige kreftformene vi kjenner til. Eksisterende behandlingsmetoder inkluderer stråling og kjemoterapi, men forventet forlenget levetid som følge av behandling er dessverre kun to en halv måned (fra litt over tolv måneder til fjorten og en halv måned)....

Tildelt: kr 0,50 mill.

Prosjektperiode: 2020-2020

Sted: Oslo

BIOTEK2021-Bioteknologi for verdiskaping

DL: Pipeline for individually tailoring new treatments in hematological cancers (PINpOINT)

Blodsykdommene som undersøkes i prosjektet har en rekke behandlingsmuligheter, men kan ofte ikke kureres. Målet med PINpOINT-prosjektet er å utvikle og validere metoder for å kunne teste effekter av biblioteker av tilgjengelige kreftlegemidler på pasientprøver utenfor kroppen. Vi undersøker effe...

Tildelt: kr 20,4 mill.

Prosjektperiode: 2019-2023

Sted: Oslo

FORINFRA-Nasj.sats. forskn.infrastrukt

Participation of NOR-OPENSCREEN in the Nordic Chemical Biology Consortium (NCBC) and the ESFRI project EU-OPENSCREEN.

Chemical Biology (CB) is defined as exploring biology by the use of small organic molecules and natural compounds. There is an increasing need for new bioactive compounds in many fields of Life Sciences and bioactive chemical compounds constitute the most common form of medical therapies and are ...

Tildelt: kr 0,25 mill.

Prosjektperiode: 2015-2016

Sted: Oslo

BIOTEK2021-Bioteknologi for verdiskaping

Compounds that regulate phospholamban phosphorylation with possible cardioprotective effect in the post-infarction heart

Successful acute trombolytic treatment of myocardial infarction (MI, 1.2 mill cases i 7 markets) creates more damaged hearts and a medical need for better post-MI treatment. The adrenalin-beta-adrenergic receptor-cAMP-protein kinase A signalling pathway r egulates heart rate and contractility. Al...

Tildelt: kr 5,8 mill.

Prosjektperiode: 2013-2017

Sted: Oslo

BIOTEK2021-Bioteknologi for verdiskaping

Development of technology for flow cytometry- and other cell-based, high-content, high-throughput analyses to support marine bioprospecting

ChemBioNet Norway - Norwegian Chemical Biology Platforms is a national network of HTS screening platforms (part of ESFRI-project EU-Openscreen) that support marine bioprospecting and drug screening. A joint application to the Infrastructure Programme for investments to support marine bioprospect...

Tildelt: kr 4,0 mill.

Prosjektperiode: 2011-2015

Sted: Oslo

FRIMEDBIO-Fri prosj.st. med.,helse,biol

Therapeutic Strategies to Interfere with Inhibition of Anti-tumor Immune Activity Mediated by Regulatory T cells

Prosjektet undersøker en type hvite blodlegemer (regulatoriske T celler) som hemmer andre T celler i immunforsvaret og justerer immunresponser. Disse regulatoriske cellene er normalt viktige for å forhindre autoimmunitet og reumatiske sykdommer. Hvis de derimot virker for sterkt kan det bidra ...

Tildelt: kr 7,8 mill.

Prosjektperiode: 2011-2015

Sted: Oslo

FORINFRA-Nasj.sats. forskn.infrastrukt

Participation of ChemBioNet Norway NOR-OPENSCREEN in ESFRI-preparatory phase project EU-OPENSCREEN

Chemical Biology (CB) is defined as exploring biology by the use of small organic molecules and natural compounds. There is an increasing need for new bioactive compounds in many fields of Life Sciences and bioactive chemical compounds constitute the most common form of medical therapies and are...

Tildelt: kr 0,49 mill.

Prosjektperiode: 2011-2013

Sted: Oslo

FORINFRA-Nasj.sats. forskn.infrastrukt

Norwegian participation in the European Advanced Translational Research Infrastructure in Medicine (EATRIS)

Traditionally, biomedical research in Europe has been strong. Comparing the biomedical research budgets in the US to the EU, the output in publications and citations of European scientists is more than competitive. However, the transition from research di scovery to clinical product has not kept ...

Tildelt: kr 0,44 mill.

Prosjektperiode: 2010-2012

Sted: Oslo

FRIBIO-Biologi og biomedisin

3rd International Conference on Compartmentalized cAMP Signaling (jointly with FEBS Workshop on Spatiotemporal Dynamics of Cell Signaling)

There is a need for European and international scientists in the area of cell signaling to get together and bring attention to new subjects such as spatiotemporal organization, compartmentalized cAMP and modeling of signaling. Furthermore, European scient ists should get together for networking t...

Tildelt: kr 0,15 mill.

Prosjektperiode: 2010-2011

Sted: Oslo

BIA-Brukerstyrt innovasjonsarena

Chemical Biology Platform by ChemBioNet Norway - Knowledge-building Project with User Involvement (KMB)

Chemical biology (CB) involves use of small molecules to perturb and study biological function. Small molecular compounds (SMC) with molecular weight below 500 Da have proven extremely important to explore function at the molecular, cellular, and in vivo level and for treating diseases. Most med...

Tildelt: kr 6,0 mill.

Prosjektperiode: 2009-2012

Sted: Oslo

FRIMEDBIO-Fri prosj.st. med.,helse,biol

Spatiotemporal Regulation of cAMP Signalling in Health and Disease

Signalling networks involving the signal molecule cAMP and protein kinase A (PKA) are involved in regulation of a multitude of body functions involving most organ systems of the body. An emerging principle is that function of the cAMP signal pathway in th ese settings requires subcellular anchori...

Tildelt: kr 6,0 mill.

Prosjektperiode: 2009-2014

Sted: Oslo

FRIBIO-Biologi og biomedisin

Workshop on Dynamics of Cell Signal Systems (cofunded with FEBS)

There is a need for European and international scientists in the area of cell signaling to get together and bring attention to new subjects such as spatiotemporal organization and modeling of signaling. Furthermore, European scientists should get togethe r for networking to strengthen and increa...

Tildelt: kr 0,15 mill.

Prosjektperiode: 2008-2008

Sted: Oslo

GNBIO-Grunnleggende næringsrettet bioteknologi

Targeting of a PKA-AKAP18d-phospholamban signalling complex in the heart as therapy for chronic heart failure

The adrenalin-beta-adrenergic receptor-cAMP-protein kinase A signalling pathway regulates heart rate and contractility. Although changes in cardiac myocyte contractility either cause or are associated with cardiovascular disease, surprisingly few drugs ar e available that modulate the cardiac myo...

Tildelt: kr 2,8 mill.

Prosjektperiode: 2007-2012

Sted: Oslo

BIA-Brukerstyrt innovasjonsarena

Drug targeting of protein-protein and ligand-protein interactions

Chemical biology (CB) involves use of small molecules to perturb and study biological function. Small molecular compounds (SMC) with molecular weight below 500 Da have proven extremely important to explore function at the molecular, cellular, and in vivo level and for treating diseases. Most medi...

Tildelt: kr 7,2 mill.

Prosjektperiode: 2007-2011

Sted: Oslo

TU-Tungt utstyr

High resolution multi-dimensional imaging of cell signalling networks.

The Biotechnology Centre of Oslo (BiO) at the University of Oslo is a centre for functional genomics, currently consisting of six internationally competitive research groups headed by Drs. Taskén, Nilsen, Thiede, Chaudhry, Donaldson and Leitges. BiO also has an open position for a seventh new gro...

Tildelt: kr 2,7 mill.

Prosjektperiode: 2007-2007

Sted: Oslo

FORNY-3-Kommersialisering av FoUresultater

Molecular disruptors of cAMP signalling complex in the heart as therapy for chronic heart failure

...

Tildelt: kr 1,1 mill.

Prosjektperiode: 2007-2007

Sted: Oslo

BIA-Brukerstyrt innovasjonsarena

Innovation on Signalling Disruptors - Development of drugs eliminating cAMP action in infectious disease (HIV/AIDS) and cancer

Compartmentalised cAMP-dependent signalling is involved in development of a number of diseases including HIV/AIDS, certain types of cancer, and other types of immunodeficiencies which affect several million citizens both in industrialised and developing c ountries each year. No organised approach...

Tildelt: kr 6,0 mill.

Prosjektperiode: 2007-2009

Sted: Oslo

FORNY-3-Kommersialisering av FoUresultater

Molecular disruptors of cAMP signalling complex in the heart as therapy for chronic heart failure

...

Tildelt: kr 0,36 mill.

Prosjektperiode: 2006-2006

Sted: Oslo

FUGE-Funksjonell genomforskn.i Norg

Functional Genomics of Regulatory T cells - Novel Therapeutic Strategies for Immunomodulation

The main goal of the research plan is to understand how the immune system controls immune reactivity and balances self-tolerance versus an efficient immune defence. This could potentially lead to new understanding of key factors in the pathogenesis of hum an disease. Specifically, we aim to inves...

Tildelt: kr 7,0 mill.

Prosjektperiode: 2006-2010

Sted: Oslo

FRIBIO-Biologi og biomedisin

Modulation of a PKA-Csk-Lck inhibitory pathway in T cell lipid rafts by CD28-mediated recruitment of a b-arrestin/phosphodiesterase complex

The goal of this project is to understand the molecular mechanisms for cAMP inhibition of lymphocyte proliferation and immune functions. Specifically, we want to understand the molecular interactions and spatio-temporal regulation of the newly mapped PKA- type I-Csk inhibitory pathway regulating ...

Tildelt: kr 2,9 mill.

Prosjektperiode: 2006-2009

Sted: Oslo

FRIMED-Klinisk medisin og folkehelse

Novel therapeutic strategies for immunostimulation in HIV targeting CD25+ T-regulatory cells.

Regulatory T cells (Treg) represent 5-10% of the CD4 T cells and are identified by constitutively expressing CD25. Treg are subdivided into naturally occuring Treg devolped in the thymus, and adaptive Treg that are induced in the periphery from naïve CD4 T cells. Naturally occuring Treg are intst...

Tildelt: kr 2,4 mill.

Prosjektperiode: 2006-2008

Sted: Oslo

KREFTSATS-Særutlysning kreftmidler, historikk

Novel therapeutic strategies for stimulation of anti-neoplastic immune activity

More than 20% of the human genome encodes proteins that are devoted to cellular signalling. Signal networks that involve the signal molecule cyclic AMP (cAMP) are involved in diseases such as cancer, cardiovascular disease, type II diabetes, obesity, HIV and asthma. Cyclic AMP acts as an acute in...

Tildelt: kr 6,0 mill.

Prosjektperiode: 2005-2007

Sted: Oslo

FUGE-Funksjonell genomforskn.i Norg

Development of immunostimulatory therapy disrupting the hyperactivated cAMP signalling pathway in HIV immunodeficiency

LAURAS is developing immunostimulatory drugs that will reverse the immunodeficiency in HIV and other immunodeficiencies. Such treatment is called for since the present antiretroviral treatment (HAART) does not offer cure for the disease, is associated wit h resistance and has significant side eff...

Tildelt: kr 4,7 mill.

Prosjektperiode: 2005-2007

Sted: Oslo

YFF-Yngre, fremragende forskere

Toppforskningsprogrammets prosjekt ledet av Kjetil Tasken

...

Tildelt: kr 4,2 mill.

Prosjektperiode: 2004-2007

Sted: Oslo

FUGE-Funksjonell genomforskn.i Norg

Søknad om støtte til ESF 2005 European Functional Genomics Conference

...

Tildelt: kr 0,40 mill.

Prosjektperiode: 2004-2007

Sted: Oslo

FUGE-Funksjonell genomforskn.i Norg

Novel signalling disruptors and enhancers that affect function of the cAMP signalling pathway

This Proposal outlines plans for further development of a research group competing at an international level in the field of cell signalling. The group employs functional genomics and platform technologies in the national FUGE programme to identify new genes implicated in specific pathways and ne...

Tildelt: kr 8,0 mill.

Prosjektperiode: 2004-2007

Sted: Oslo

TU-Tungt utstyr

Utstyr for Protein-protein samhandling i cellesignal

Anchored and scaffolded signalling pathways involving kinases and phosphatases are implicated in major chronic diseases such as HIV, cancer, diabetes type II, cardiovascular disease, and also underpins various genetic diseases. However, no systematic app roach has explored the therapeutic potent...

Tildelt: kr 1,7 mill.

Prosjektperiode: 2004-2005

Sted: Oslo

BIOMOL-Molekylær biovitenskap og bioteknologi

Strategies for disruption of a cAMP-PKA-Csk inhibitory pathway assembled in lipid rafts that regulates Src-kinase signaling

...

Tildelt: kr 1,7 mill.

Prosjektperiode: 2004-2006

Sted: Oslo